Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.
BMC Med
; 21(1): 423, 2023 11 07.
Article
in En
| MEDLINE
| ID: mdl-37936166
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Nasopharyngeal Neoplasms
/
Neoplasm Recurrence, Local
Limits:
Humans
Language:
En
Journal:
BMC Med
Journal subject:
MEDICINA
Year:
2023
Type:
Article